Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence
Quest Diagnostics (NYSE: DGX) announced significant leadership changes to support its strategy for growth and operational excellence. CEO-Elect Jim Davis appointed Karthik Kuppusamy as Senior VP of Clinical Solutions, Mark Gardner as Senior VP of Molecular Genomics and Oncology, and Kristin Wallace as Senior VP of Compliance. These seasoned executives are expected to bolster the company’s innovation and compliance leadership post-pandemic. The appointments reflect Quest's commitment to enhancing its market position in diagnostic services.
- Appointment of Karthik Kuppusamy as Senior VP of Clinical Solutions to drive innovative diagnostic solutions.
- Creation of a new role for Mark Gardner as Senior VP of Molecular Genomics and Oncology to enhance growth in advanced diagnostics.
- Kristin Wallace promoted to Senior VP of Compliance, ensuring strong ethics and regulatory oversight.
- None.
SECAUCUS, N.J., Oct. 13, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced Jim Davis, CEO-Elect, has made several organizational changes and leadership appointments of seasoned executives to better support the company's two-point business strategy to accelerate growth and drive operational excellence:
- Karthik Kuppusamy, Ph.D., is named Senior Vice President, Clinical Solutions.
- Mark Gardner has been appointed Senior Vice President, Molecular Genomics and Oncology, a new position.
- Kristin Wallace is now Senior Vice President, Compliance, succeeding Tim Sharpe, who retired in August.
"These latest appointments continue to strengthen Quest's leadership team and position us well to continue to innovate in a post-pandemic healthcare environment," said Mr. Davis. "Both Karthik and Kristin are proven Quest leaders and are ready to assume additional responsibilities within our team. Mark comes to Quest with deep knowledge in molecular genomics, genetic sequencing and oncology, combined with commercial and technology expertise which are critical as we drive growth in these areas."
"We have made substantial progress in our transition to new leadership, as evidenced by the strong team Jim Davis has built," said Steve Rusckowski, Chairman, CEO and President. "Quest is well-positioned in the market and Jim has a great leadership team in place as we pursue the next phases of growth and development."
Mr. Kuppusamy is responsible for bringing innovative diagnostic solutions to market through Quest's clinical franchises as well as Pharma Services, Genomic Services, and Global Markets, in partnership with the company's highly capable Medical and Research & Development teams. Previously, he led the North region as General Manager, based at the lab in Marlborough, MA. Before that, he led the Neurology franchise.
He earned a B.S. in electronics and communications engineering from Anna University and a M.S. in biomedical engineering from the Indian Institute of Technology, both in India. He also holds an M.B.A. in finance and operations from Marquette University and a Ph.D. in electrical and biomedical engineering from Washington University in St. Louis.
In his newly created role, Mr. Gardner is responsible for driving growth in Quest's Advanced Diagnostics offerings by providing genetic sequencing services, cancer diagnostics and working closely with the company's clinical franchises. He joins Quest from Corza Medical, a private equity operating company focused on surgical technologies and tools, where he served as Executive Partner, SVP and GM of European Commercial Operations and Biosurgery Products. He built a career in molecular genomics, next generation sequencing and oncology diagnostics, having served at a range of companies that include Thermo Fisher Scientific, Life Technologies, Invitrogen and Omniseq. He began his private sector career as a McKinsey consultant after serving in the U.S. Navy, where he reached the rank of Lieutenant Commander. He earned a BS degree from the U.S. Naval Academy, an MA in National Security Studies from Georgetown University, and an MBA from the Wharton School at the University of Pennsylvania.
As the compliance leader, Kristin Wallace is responsible for maintaining and building on Quest's industry leadership in ethics, integrity, compliance, and privacy. Ms. Wallace joined Quest in 2009 in the legal department as Senior Corporate Counsel. Over the years, she has provided legal support for the company's operations, franchises, pricing, regulatory, privacy, compliance, billing, and Quest for Health Equity. Most recently, as the Chief Regulatory Counsel, she worked closely to oversee FDA review of new tests to support Quest's COVID-19 response. She earned a bachelor's degree from West Chester University of Pennsylvania, and a J.D. degree from Villanova Law School.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-announces-organizational-changes-to-accelerate-growth-and-drive-operational-excellence-301648032.html
SOURCE Quest Diagnostics
FAQ
What leadership changes did Quest Diagnostics announce on October 13, 2022?
Who is the CEO-Elect of Quest Diagnostics?
What is the focus of the new roles at Quest Diagnostics?
What is the significance of the appointment of Mark Gardner at Quest Diagnostics?
How will Karthik Kuppusamy contribute to Quest Diagnostics?
